Incyte drops HIV drug
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Incyte is discontinuing development of its HIV candidate dexelvucitabine (DFC, formerly Reverset) due to "a recently observed increase in the frequency of grade 4 hyperlipasemia" in the firm's long-term extension of a Phase IIb trial, the firm says April 3. "Based on these observations, Incyte believes it is in the best interests of patients to discontinue development of DFC and has decided to stop enrollment of [a] recently initiated Phase IIb trial," the firm says. Incyte previously had cited hyperlipasemia, or pancreatic inflammation, as one of FDA's reasons for not giving a green light for the firm's Phase III program (1Pharmaceutical Approvals Monthly October 2005, p. 6). Incyte notes that "even though lower doses [of DFC] could be safer, those we've studied have not been effective," further reinforcing the decision to discontinue the nucleoside analog reverse transcriptase inhibitor...
You may also be interested in...
Incyte Reverset Program Delayed 12-18 Months For Confirmatory Study
FDA's refusal to green-light Phase III study plans for Incyte's Reverset HIV therapy could delay market launch by at least a year, according to the company
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.